×
Rian Johnson Aimed to Make the ‘Empire Strikes Back’ of the ‘Star Wars’ Sequels

Rian Johnson Aimed to Make the ‘Empire Strikes Back’ of the ‘Star Wars’ Sequels

When talking about his time in Star Wars, Rian Johnson often says that he’d like to return to that world one day, at least once he stops making murder-mystery movies and TV shows. But while fans continue to hope he’ll make that once-planned trilogy one day, others can’t quite get past the seeming disappointments contained in his franchise entry, The Last Jedi. In a new interview, Johnson recalls what he was told when he came aboard the Lucasfilm project.

Speaking to Rolling Stone, Johnson addressed the notion that he and J.J. Abrams—who made the first and third films in the sequel trilogy, The Force Awakens and The Rise of Skywalker—didn’t communicate enough about their 2015 and 2017 Star Wars films, leading to a disjointed feeling between the two.

That’s not the case, Johnson said. “We met and I spent days with him and was able to get into his head and all the choices he had made. That having been said, I communicated and I went and made the movie. And he was in the middle of Force Awakens. Ultimately, I feel like the choices in it, none of them were born out of an intent to ‘undo’ anything. They were all [born] out of the opposite intent of, how do I take this story that J.J. wrote, that I really loved, and these characters he created that I really loved, and take them to the next step?”

An authority stepped in for some guidance at this point, Johnson said. “Kathy [Kennedy, the president of Lucasfilm] said, ‘We’re looking at someone to do the Empire [Strikes Back] of this series.’ I took that assignment very seriously. Maybe more seriously than someone would have liked. I guess to me that didn’t mean making something that just had nods to Empire—that meant trying to genuinely do what Empire did.”

Whether or not Johnson’s interpretation of Empire pleased fans (some people don’t mind The Last Jedi!), it’s clear that coming into the franchise to make the middle film in the series was no easy task. That became even tougher when Johnson tried to put his own stamp on the story so far—including, as Rolling Stone uses as an example, doing away with Snoke, the big bad set up with much fanfare in The Force Awakens. Turns out Johnson just thought Kylo Ren was a “more compelling and complicated villain.”

“To me, I didn’t easily dispense with Snoke. I took great pains to use him in the most dramatically impactful way I could, which was to then take Kylo’s character to the next level and set him up as well as I possibly could. I guess it all comes down to your point of view.”

And really, what would Star Wars be without heated fan debates over the choices made, on-screen and off?

Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what’s next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.

Source link
#Rian #Johnson #Aimed #Empire #Strikes #Star #Wars #Sequels

confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date

OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo
How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says

How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

Post Comment